HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA "informal rulemaking" prohibition proposed in House Budget Cmte. FY 1996 resolution.

This article was originally published in The Rose Sheet

Executive Summary

FDA "INFORMAL RULEMAKING" PROHIBITION PROPOSED BY HOUSE BUDGET CMTE. in its report on the fiscal year 1996 budget resolution. "The FDA currently makes policy through a variety of improper means" such as "points to consider" documents, draft guidances, speeches and warning letters, according to the report. These activities, which "are difficult to track yet often contain substantive rules," should be eliminated by withholding funding for them through the appropriations process, the committee report states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel